CACNA2D3 and neuroblastoma: MYCN non-amplified neuroblastoma patients with lower expression levels of ALCAM, CACNA2D3, DST, EPB41L4A or KIF1B were with lower overall survival in TARGET dataset (Fig. 5a), GSE49710 dataset (Fig. 5b) and GSE85047 dataset (Fig. 5c).